Review of raloxifene and its clinical applications in osteoporosis

Bibliography

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Treatment. JAMA (2001) 285:785–795.
   PubMed Web of Science ®Google Scholar
• KANIS JA, MELTON LJ (III), CHRISTIANSEN C: The diagnosis of osteoporosis. J. Bone Miner. Res. (1994) 9:1137–1141.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, THOMPSON DE, ENSRUD KC, SCOTT JC, BLACK D: Risk of mortality following clinical fractures. Osteoponos. hat. (2000) 11:556–561.
   PubMed Web of Science ®Google Scholar
• RAY NF, CHAN JK, THAEMER M, MELTON LJ (III): Medical expenditures for the treatment of osteoporotic fractures in the United States in (1995) report from the National Osteoporosis Foundation. J. Bone Miner. Res. (1997) 12:24–35.
   PubMed Web of Science ®Google Scholar
• GULLBERG B, JOHNELL O, KANIS JA: World-wide projections for hip fracture. Osteoporos. mt. (1997) 7:407–413.
   PubMed Web of Science ®Google Scholar
• ETTINGER B, BLCK DM, MITLAK BH et al.: Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA (1999) 282:637–645.
   Google Scholar
• CHESNUT C, III,SILVERMAN SL, ANDRIANO K et al.: Nasal spray salmon calcitonin safely and persistently reduces the risk of new vertebral fractures in postmenopausal women with established osteoporosis: the PROOF Study. Am.,/ Med. (2000) 109:267–276.
   Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet (1996) 348:1535–1541.
   PubMed Web of Science ®Google Scholar
• HARRIS ST, WATTS NB, GENANT HKet al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA (1999) 282:1344–1352.
   Google Scholar
• NEER RIVI, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. (2001) 344:1434–1441.
   PubMed Web of Science ®Google Scholar
• MCCLUNG MR, GEUSENS P, MILLER PD et al: Effect of risedronate on the risk of hip fracture in elderly women. N Engl. J. Med. (2001) 344:333–340.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK, ZHAO H, FUQUA SA: Selective oestrogen receptor modulators. Structure, function and clinical use. J. Clin. Oncol. (2000) 18:3172–3186.
   PubMed Web of Science ®Google Scholar
• JORDAN CV: Selective oestrogen receptor modulation: a personal perspective. Cancer Res. (2001) 51:5683–5687.
   Google Scholar
• PLOUFFE L: Selective oestrogen receptor modulators (SERMs) in clinical practice.' Soc. Gynecol Investig. (2000) 7:S38–S45.
   Google Scholar
• BAKER VL, JAFFE RB: Clinical uses of antiestrogens. °Lister Gynecol. Surv. (1996) 51:45–59.
   PubMedGoogle Scholar
• JENSEN EV, GREENE GL, CLOSS LE et al.: Receptors reconsidered; a 20-year perspective. Recent Prog. Horm. Res. (1982) 38:1–40.
   PubMedGoogle Scholar
• BRYANT HU: Mechanism of action andpreclinical profile of raloxifene, a selective oestrogen receptor modulator. Rev Endo. Metabol Dis. (2001) 2:129–138.
   PubMedGoogle Scholar
• CHEN Z, YUHANNA IS, GALCHEVA-GARGOVA Z et al.: Oestrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by oestrogen. J. Gin. Invest. (1999) 103:401–406.
   PubMed Web of Science ®Google Scholar
• KUIPER GG, CARLSSON B, GRANDIEN K et al.: Comparison in the ligand binding specificity and transcript tissue distribution of oestrogen receptors alpha and beta. Endocrinology (1997) 138:863–870.
   PubMed Web of Science ®Google Scholar
• WIJAYARANTNE AL, NAGEL SC, PAIGE LA et al.: Comparative analysis of mechanistic differences among antiestrogens. Endocrinology (1999) 140:5828–5840.
   PubMedGoogle Scholar
• DELMAS PD, BJARNASON NH, MITLAK BH et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentration and uterine endometrium in postmenopausal women. N Engl.' Med. (1997) 337:1641–1647.
   PubMed Web of Science ®Google Scholar
• LUFKIN EG, WHITAKER MD, NICKELSEN T et al.: Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. ./. Bone Miner. Res. (1998) 13:1747–1753.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, VIGNOT E, GARNERO P et al.: Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporosis Int. (1999) 10:330–336.
   PubMed Web of Science ®Google Scholar
• GENANT HK, WU CY, VAN KUIJK C, NEVITT MC: Vertebral fracture assessment using a semiquantitative technique.' Bone Miner. Res. (1993) 8:1137–1148.
   PubMed Web of Science ®Google Scholar
• SILVERMAN SL, MINSHALL ME, SHEN W, HARPER KH, XIE S: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum. (2001) 44:2611–2619.
   PubMed Web of Science ®Google Scholar
• MARICIC M, ADACHIJ, MEUNIER P etal.: Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch. Int. Med. (2002). In Press.
   Google Scholar
• BJARNASON NH, SARKAR S, DUONG T et al.: Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporosis Int. (2001) 12:922–930.
   PubMed Web of Science ®Google Scholar
• SARKAR S, MITLAK BH, WONG M et al.: Relationships between bone mineral density and vertebral fracture risk with raloxifene therapy. Bone Miner. Res. (2002) 17:1–10.
   PubMed Web of Science ®Google Scholar
• PRESTWOOD KM, GUNNESS M, MUCHMORE DB et al.: A comparison of the effects of raloxifene and oestrogen on bone in postmenopausal women. Clin. Endocrinol. Metab. (2000) 85:2197–2202.
   Google Scholar
• POLS H, EASTELL R, DELMAS P: Early onset and sustained efficacy of raloxifene on incident vertebral fractures in post-menopausal women with osteoporosis: 4-year results from the MORE trial. Bone 28(5):S85.
   Google Scholar
• CAULEY JA, LUCAS FL, KUILER LH et al.: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: study of Osteoporotic Fracture Research Group. Ann. Intern. Med. (1999) 130:270–277.
   PubMed Web of Science ®Google Scholar
• FREEDMAN M, SAN MARTIN J, O'GORMAN J et al: Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, oestrogen or placebo Nati Cancer Inst. (2001) 93:51–56.
   Google Scholar
• CUMMINGS S, ECKERT S, KRUEPER K et al.: The effect of raloxifene or risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA (1999) 281:2189–2197.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, NORTON L, LIPPMAN ME et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4 year results from the MORE trial. Br. Cancer Res. Treat. (2001) 65:125–134.
   PubMed Web of Science ®Google Scholar
• LIPPMAN ME, KRUEGER KA, ECKERT S et al.: Indicators of lifetime oestrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. I Clin. Oncol. (2001) 19:3111–3116.
   PubMed Web of Science ®Google Scholar
• SAITTA A, ALTAVILLA D, CUCINOTTA D et al.: Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. (2001):21:1512–1519.
   PubMed Web of Science ®Google Scholar
• WALSH BW, KULLER LH, WILD RA et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA (1998) 279:1445–1451.
   PubMed Web of Science ®Google Scholar
• WALSH BW, PAUL S, WILD RA et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. Clin. Endocrinol. Metab. (2000) 85:214–218.
   Google Scholar
• BARRETT-CONNOR E, GRADY D, SASHEGUI A et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA (2002) 287:847–856.
   PubMed Web of Science ®Google Scholar
• HULLEY J, GRADY D, BUSH T et al.: Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and oestrogen/progestin Replacement Study (HERS) Research Group. JAMA. (1998) 280(7):605–613.
   Google Scholar
• MOSCA L, BARRETT-CONNOR E, WENGER NK et al.: Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am. j Cardiol (2001) 88:392–395.
   PubMed Web of Science ®Google Scholar
• DAVIES GC, HUSTER WJ, SHEN W etEndometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy and unopposed oestrogen in postmenopausal women. Menopause (1999) 6:188–195.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SR, NEVEN P, ZHOU L et Raloxifene effect on frequency of surgery for pelvic floor relaxation. Ob. Gyn. (2001) 98:91–96.
   PubMed Web of Science ®Google Scholar
• PALOMBA S, SAMMARTINO A, DI CARLO C et al.: Effects of raloxifene treatment on uterine leiomyomas in 774 postmenopausal women. Fertility & Sterility (2001) 76:38–43.
   Google Scholar
• YAFFE K, KRUEGER K, SARKAR S et al:Cognitive function in postmenopausal women treated with raloxifene. N Engl. Med. (2001) 344:1207–1213.
   PubMed Web of Science ®Google Scholar
• KAYSERI ETTINGER B, PRESSMAN A: Postmenopausal hormonal support: discontinuation of raloxifene versus oestrogen. Menopause (2001) 8:328–332.
   PubMedGoogle Scholar